Oncology

Donald Moore discusses some of the obstacles that bispecific antibodies have faced in community cancer centers, including misconceptions coupled with a prevalent toxicity profile.

Jose Tinajero discusses how certain mutations can be indicators of blinatumomab treatment failure in patients with B-cell acute lymphoblastic leukemia.

Mazyar Shadman, MD, MPH, discusses the continued efficacy of zanubrutinib in patients with chronic lymphocytic leukemia.

Durvalumab could offer further treatment for individuals with muscle-invasive bladder cancer.

Pharmacists can educate and encourage screenings for colon cancer to ensure it is discovered as early as possible.

The authors suggest that targeted interventions to mitigate financial toxicity should be implemented to better support patients.

The indication is for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy.

Sacituzumab tirumotecan (sac-TMT; Kelun Pharmaceutical, Merck) is currently being studied to treat non-small cell lung cancer (NSCLC) in the TroFuse-004 and TroFuse-009 trials.

The American Society of Hematology (ASH) Annual Meeting and Exposition will include the latest news and clinical trial updates in the hematology field.

Clinicians' enthusiasm for cell and gene therapies is tempered by practical concerns.

High-dose vitamin C, when combined with chemotherapy, has shown the potential to double the survival rate of patients with late-stage metastatic pancreatic cancer.

The therapy has similar benefits for both older and younger patients with multiple myeloma.

The tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.

AI-powered drug response prediction technology is revolutionizing veterinary and human oncology by enabling personalized treatment plans through live cell testing, machine learning models, and data-driven precision medicine approaches.

When different skin tones are considered in imaging systems, women will receive more equitable screening and care.

Potential solutions can include international funding, improved primary health care measures, and cost-effective screening methods.

Trends across small cell lung cancer (SCLC) and diffuse large B-cell lymphoma (DLBCL) emphasize the need to further improve global treatment options.

Because these cells are present throughout the body, there may also be implications for other cancer types.

Lisocabtagene maraleucel chimeric antigen receptor T-cell therapy significantly enhances treatment of relapsed/refractory B-cell malignancies, offering high response rates and durable remissions.

However, the monthly expenditure was not significantly associated with the financial incentives.

Pharmacists play a vital role in multidisciplinary health care teams by enhancing medication safety, optimizing therapeutic outcomes, expanding medication access, reducing costs, and improving patient education.

This is the first oral liquid form of imatinib (Imkeldi; Shorla Oncology) to be approved to treat cancers.

Data show that a child’s insurance status is independently associated with mortality after hematopoietic cell transplantation.

The guidelines were expanded to include the growing use of genetic testing within cancer prevention, screening, and treatment.

Rusfertide may sustain hematocrit levels in patients with polycythemia vera.

The risk of developing interstitial lung disease after immunotherapy was 6.5 times higher in individuals with high inflammation.

The supplemental new drug application (sNDA) is based on results from a phase 3 trial that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC).

There were 2 main types of switches, including switching to rituximab subcutaneous and switching among different intravenous rituximab treatments.

ALE.P02 could provide further treatment options for advanced or metastatic anti–claudin-1+ squamous cancers.

The indication is for adults with previously treated unresectable or metastatic HER2+ (IHC+) biliary tract cancer (BTC) as detected by an FDA-approved test.